Sio Gene Therapies : Secures FDA Fast Track Designation for Gene Therapy Candidate for GM1 Gangliosidosis-- Sio Gene Therapies said Thursday the US Food and Drug Administration has granted fast track designation for AXO-AAV-GM1, a gene therapy candidate for the treatment of Type I and Type II GM1...